enGene (ENGN)

Executive Summary

enGene Inc. (NASDAQ: ENGN) is a Canadian biotechnology company pioneering non-viral gene therapies for localized delivery to mucosal tissues, with a primary focus on gastrointestinal and urological diseases. Its proprietary platform enables efficient gene transfer using non-viral vectors, aiming to reduce treatment burden and improve clinical outcomes. The company's sole pipeline candidate is detalimogene (EG-70), a non-viral gene therapy in a Phase 1/2 clinical trial for non-muscle invasive bladder cancer (NMIBC), specifically in patients with carcinoma in situ. This trial (NCT04752722) began in 2021 and is currently recruiting, with a projected completion date of November 2028. enGene went public via a de-SPAC merger and has a market capitalization of approximately $110 million as of mid-2026. The company's concentrated strategy on a single asset in a high-unmet-need area positions it for potential value inflection points in the near term. enGene's near-term catalysts revolve around the advancement of EG-70. Key upcoming milestones include interim efficacy and safety data readouts from the ongoing Phase 1/2 study, which could validate the platform and de-risk NMIBC treatment. Additionally, completion of enrollment and potential updates on regulatory interactions, such as an End-of-Phase 2 meeting with the FDA, are expected within the next 12–18 months. Given the early-stage nature and single-asset dependence, the stock carries significant binary risk, but positive data could rapidly re-rate the company, making it a high-conviction speculative opportunity in the biotech space.

Upcoming Catalysts (preview)

• Q1 2027Interim Phase 1/2 data readout for EG-70 in NMIBC50% success
• Q4 2026Completion of patient enrollment in Phase 1/2 trial80% success
• H2 2027FDA meeting or guidance on potential accelerated approval path35% success